Skip to main content
main-content

25.05.2019 | Observational Research | Ausgabe 8/2019

Rheumatology International 8/2019

Quality of life among female patients with systemic lupus erythematosus in remission

Zeitschrift:
Rheumatology International > Ausgabe 8/2019
Autoren:
Rudra Prosad Goswami, Rudrani Chatterjee, Parasar Ghosh, Geetabali Sircar, Alakendu Ghosh
Wichtige Hinweise
Rudra Prosad Goswami and Rudrani Chatterjee are joint first authors.
We confirm that the current article is not under consideration or published elsewhere. A part of the data was analysed and was accepted in the EULAR, 2018 congress for presentation [Goswami R, Chatterjee R, Mitra A, et al. THU0375 Quality of life in indian patients with systemic lupus erythematosus in durable remission: psychosocial and demographic factors Annals of the Rheumatic Diseases 2018;77:404].

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abstract

The objective is to assess quality-of-life (QoL) parameters among Indian female systemic lupus erythematosus (SLE) patients with durable remission. Indian female SLE patients in remission determined by the European consensus criteria and age-matched female control participants were included in the study. All included participants underwent measurements of QoL [Medical Outcomes Study Short-Form-12 (SF12)], Fatigue Severity Scale, and structured interview with a clinical psychologist. The population comprised of 126 female SLE patients [median age: 27.5 years [interquartile range (IQR): 11]; median disease duration: 36 months (IQR 26)] and 110 female controls [median age 30 years (IQR 9)]. Clinical remission was seen in 65.9% (83/126) and complete remission in 34.1% (43/126). Significant fatigue was present in 18.3% (23/126). Both SF-12 physical component summary (PCS) and mental component summary (MCS) were similar between SLE patients and controls [median PCS: 50.3 (IQR: 16.2) vs. 48.6 (IQR: 11.6); median MCS: 57.2 (IQR: 4.8) vs. 57.9 (IQR: 7.6)]. In generalised linear modelling, PCS was associated with fatigue [odd’s ratio (OR) 0.012, 95% confidence interval (CI) 0.006–0.025, p < 0.001], disease duration ≥ 5 years (OR 23.16, 95% CI 1.548–346.58, p = 0.023), and complete remission (OR 33.16, 95% CI 4.43–248.15, p = 0.001); MCS with fatigue (OR 0.53, 95% CI 0.34–0.84, p = 0.007) and absence of depression (OR 3.65, 95% CI 1.07–12.44, p = 0.038). Patients with SLE in remission report significant fatigue in 18.3% of subjects. Both PCS and MCS scores are similar to healthy controls. Better PCS was associated with less fatigue, longer disease duration, and complete remission. Better MCS was associated with less fatigue and absence of depression.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt e.Med zum Sonderpreis bestellen!

Sichern Sie sich jetzt Ihr e.Med-Abo und sparen Sie 50 %!

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 8/2019

Rheumatology International 8/2019 Zur Ausgabe
  1. Sie können e.Med Innere Medizin 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.